Renal Effects of Anti-angiogenesis Therapy: Update for the Internist

Folkman, 1971, Tumor angiogenesis, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108 Izzedine, 2007, Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension, Am J Kidney Dis, 50, 203, 10.1053/j.ajkd.2007.04.025 Ferrara, 1999, Molecular and biological properties of vascular endothelial growth factor, J Mol Med, 77, 527, 10.1007/s001099900019 Maharaj, 2006, Vascular endothelial growth factor localization in the adult, Am J Pathol, 168, 639, 10.2353/ajpath.2006.050834 Esser, 1998, Vascular endothelial growth factor induces endothelial fenestrations in vitro, J Cell Biol, 140, 947, 10.1083/jcb.140.4.947 Rosen, 2000, Antiangiogenic strategies and agents in clinical trials, Oncologist, 5, 20, 10.1634/theoncologist.5-suppl_1-20 Gerber, 2008, Targeted therapies: a new generation of cancer treatments, Am Fam Physician, 77, 311 Lin, 1999, Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor, J Pharmacol Exp Ther, 288, 371 Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 357, 2666, 10.1056/NEJMoa072113 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med, 349, 427, 10.1056/NEJMoa021491 Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non–small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Emmanouilides, 2007, Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study, BMC Cancer, 7, 91, 10.1186/1471-2407-7-91 Rudge, 2007, VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade, Proc Natl Acad Sci U S A, 104, 18363, 10.1073/pnas.0708865104 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 Lameire, 2005, Acute renal failure in cancer patients, Ann Med, 37, 13, 10.1080/07853890510007205 Hurwitz, 2004, Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab, J Clin Oncol, 22, 3702, 10.1200/jco.2004.22.14_suppl.3702 Veronese, 2006, Mechanisms of hypertension associated with BAY 43-9006, J Clin Oncol, 24, 1363, 10.1200/JCO.2005.02.0503 Zhu, 2007, Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis, Am J Kidney Dis, 49, 186, 10.1053/j.ajkd.2006.11.039 Zhu, 2008, Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis, Acta Oncol, 27, 1 Wu, 2008, Incidence and risk of hypertension with sorafenib in cancer patients, Lancet Oncol, 9, 117, 10.1016/S1470-2045(08)70003-2 Hood, 1998, VEGF upregulates eNOS message, protein, and NO production in human endothelial cells, Am J Physiol, 274, H1054 Shen, 1999, Vascular endothelial growth factor governs nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway, J Biol Chem, 274, 33057, 10.1074/jbc.274.46.33057 Zou, 1999, Role of nitric oxide in the control of renal function and salt sensitivity, Curr Hypertens Rep, 1, 178, 10.1007/s11906-999-0016-7 Feihl, 2006, Hypertension, Hypertension, 48, 1012, 10.1161/01.HYP.0000249510.20326.72 Struyker-Boudier, 1988, Microcirculatory changes in cremaster muscle during early spontaneous hypertension in the rat, J Hypertens Suppl, 6, S185, 10.1097/00004872-198812040-00055 Harper, 1978, Arteriolar rarefaction in the conjunctiva of human essential hypertensives, Microvasc Res, 16, 369, 10.1016/0026-2862(78)90070-5 Castilla, 2000, Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents, Life Sci, 67, 1003, 10.1016/S0024-3205(00)00693-7 Gonzalez-Pacheco, 2006, Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2, Am J Physiol Heart Circ Physiol, 291, H1395, 10.1152/ajpheart.01277.2005 Pande, 2007, Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab, Anticancer Res, 27, 3465 Patel, 2008, A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib, J Natl Cancer Inst, 100, 282, 10.1093/jnci/djm311 Sugimoto, 2003, Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria, J Biol Chem, 278, 12605, 10.1074/jbc.C300012200 Kamba, 2007, Mechanisms of adverse effects of anti-VEGF therapy for cancer, Br J Cancer, 96, 1788, 10.1038/sj.bjc.6603813 Miller, 2005, Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer, J Clin Oncol, 23, 792, 10.1200/JCO.2005.05.098 Johnson, 2004, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer, J Clin Oncol, 22, 2184, 10.1200/JCO.2004.11.022 George, 2007, Nephrotic syndrome after bevacizumab: case report and literature review, Am J Kidney Dis, 49, 23, 10.1053/j.ajkd.2006.11.024 Eremina, 2008, VEGF inhibition and renal thrombotic microangiopathy, N Engl J Med, 358, 1129, 10.1056/NEJMoa0707330 Izzedine, 2007, Thrombotic microangiopathy and anti-VEGF agents, Nephrol Dial Transplant, 22, 1481, 10.1093/ndt/gfl565 Roncone, 2007, Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma, Nat Clin Pract Nephrol, 3, 287, 10.1038/ncpneph0476 Frangie, 2007, Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma, Lancet Oncol, 8, 177, 10.1016/S1470-2045(07)70037-2 Hara, 2006, Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis, Kidney Int, 69, 1986, 10.1038/sj.ki.5000439 Barakat, 2007, Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma, Ann Pharmacother, 41, 707, 10.1345/aph.1H635